- Book学术

发布求助

文献互助智能选刊最新文献

IF 1.9 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal Pub Date : 2025-02-09 DOI:10.1111/crj.70051

Congyi Xie, Jinzhan Chen, Shuwen Yang, Feiyang Ye, Zhenyang Lin, Yijiao Xu, Yimin Yang, Lin Tong

{"title":"Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study","authors":"Congyi Xie, Jinzhan Chen, Shuwen Yang, Feiyang Ye, Zhenyang Lin, Yijiao Xu, Yimin Yang, Lin Tong","doi":"10.1111/crj.70051","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Anlotinib is widely used in the treatment of lung cancer. However, there remains a lack of predictive biomarkers to effectively gauge the response to anlotinib therapy. We conducted a retrospective study to preliminarily explore potential risk factors that might predict outcomes in lung cancer patients undergoing anlotinib treatment.</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>We retrospectively analyzed lung cancer patients treated with anlotinib at our hospital between 1 June 2018 and 1 June 2021. Data were gathered from electronic medical records. Demographic and clinical characteristics of patients, progression-free survival (PFS), and overall survival (OS) were described. Predictive factors related to treatment efficacy were preliminarily analyzed using Cox regression and Kaplan–Meier survival analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After adjusting for potential confounders, clinical stage IV (hazard ratio [HR] = 2.52, 95% confidence interval [CI], 1.09–5.82, <i>p</i> = 0.0311), N-terminal fragment brain natriuretic peptides (NT-pro-BNP) > 300 pg/mL (HR = 2.54, 95% CI, 1.17–5.52, <i>p</i> = 0.0183), and neuron-specific enolase (NSE) > 16.3 ng/mL (HR = 1.70, 95% CI, 1.03–2.81, <i>p</i> = 0.0389) were associated with shorter OS, whereas age (HR = 0.96, 95% CI, 0.94–0.99, <i>p</i> = 0.0055) was associated with a longer PFS in fully adjusted model. Kaplan–Meier analyses of cumulative risk factors (clinical stage IV, NT-pro-BNP > 300 pg/mL, and NSE > 16.3 ng/mL) indicated that patients with a greater number of coexisting risk factors had significantly shorter OS (<i>p</i> < 0.0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Clinical stage IV, NT-pro-BNP level, and NSE level were identified as independent prognostic factors for lung cancer patients undergoing anlotinib treatment. Patients with multiple high-risk factors may derive limited benefit from anlotinib.</p>\n </section>\n </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 2","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70051","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/crj.70051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

目的：安洛替尼广泛应用于肺癌的治疗。然而，仍然缺乏预测性的生物标志物来有效地衡量对安洛替尼治疗的反应。我们进行了一项回顾性研究，初步探讨可能预测肺癌患者接受安洛替尼治疗的预后的潜在危险因素。患者和方法回顾性分析2018年6月1日至2021年6月1日在我院接受安洛替尼治疗的肺癌患者。数据是从电子病历中收集的。描述了患者的人口统计学和临床特征、无进展生存期（PFS）和总生存期（OS）。采用Cox回归和Kaplan-Meier生存分析初步分析与治疗疗效相关的预测因素。结果在调整潜在混杂因素后，临床ⅳ期（风险比[HR] = 2.52, 95%可信区间[CI]， 1.09-5.82, p = 0.0311）、n端片段脑利钠肽（NT-pro-BNP） > 300 pg/mL （HR = 2.54, 95% CI, 1.17-5.52, p = 0.0183）、神经元特异性烯醇化酶（NSE） > 16.3 ng/mL （HR = 1.70, 95% CI, 1.03-2.81, p = 0.0389）与较短的OS相关，而年龄（HR = 0.96, 95% CI, 0.94-0.99, p = 0.0389）与较短的OS相关。p = 0.0055)与完全调整模型中较长的PFS相关。Kaplan-Meier分析累积危险因素（临床分期IV期，NT-pro-BNP > 300 pg/mL, NSE > 16.3 ng/mL）表明，共存危险因素数量较多的患者生存期明显缩短（p < 0.0001）。结论临床分期、NT-pro-BNP水平、NSE水平是肺癌患者接受安洛替尼治疗的独立预后因素。具有多种高危因素的患者从安洛替尼中获益有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study

查看原文本刊更多论文

Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study

Purpose

Anlotinib is widely used in the treatment of lung cancer. However, there remains a lack of predictive biomarkers to effectively gauge the response to anlotinib therapy. We conducted a retrospective study to preliminarily explore potential risk factors that might predict outcomes in lung cancer patients undergoing anlotinib treatment.

Patients and Methods

We retrospectively analyzed lung cancer patients treated with anlotinib at our hospital between 1 June 2018 and 1 June 2021. Data were gathered from electronic medical records. Demographic and clinical characteristics of patients, progression-free survival (PFS), and overall survival (OS) were described. Predictive factors related to treatment efficacy were preliminarily analyzed using Cox regression and Kaplan–Meier survival analyses.

Results

After adjusting for potential confounders, clinical stage IV (hazard ratio [HR] = 2.52, 95% confidence interval [CI], 1.09–5.82, p = 0.0311), N-terminal fragment brain natriuretic peptides (NT-pro-BNP) > 300 pg/mL (HR = 2.54, 95% CI, 1.17–5.52, p = 0.0183), and neuron-specific enolase (NSE) > 16.3 ng/mL (HR = 1.70, 95% CI, 1.03–2.81, p = 0.0389) were associated with shorter OS, whereas age (HR = 0.96, 95% CI, 0.94–0.99, p = 0.0055) was associated with a longer PFS in fully adjusted model. Kaplan–Meier analyses of cumulative risk factors (clinical stage IV, NT-pro-BNP > 300 pg/mL, and NSE > 16.3 ng/mL) indicated that patients with a greater number of coexisting risk factors had significantly shorter OS (p < 0.0001).

Conclusion

Clinical stage IV, NT-pro-BNP level, and NSE level were identified as independent prognostic factors for lung cancer patients undergoing anlotinib treatment. Patients with multiple high-risk factors may derive limited benefit from anlotinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Respiratory Journal 医学-呼吸系统

CiteScore

3.70

自引率

0.00%

发文量

104

审稿时长

>12 weeks

期刊介绍： Overview Effective with the 2016 volume, this journal will be published in an online-only format. Aims and Scope The Clinical Respiratory Journal (CRJ) provides a forum for clinical research in all areas of respiratory medicine from clinical lung disease to basic research relevant to the clinic. We publish original research, review articles, case studies, editorials and book reviews in all areas of clinical lung disease including: Asthma Allergy COPD Non-invasive ventilation Sleep related breathing disorders Interstitial lung diseases Lung cancer Clinical genetics Rhinitis Airway and lung infection Epidemiology Pediatrics CRJ provides a fast-track service for selected Phase II and Phase III trial studies. Keywords Clinical Respiratory Journal, respiratory, pulmonary, medicine, clinical, lung disease, Abstracting and Indexing Information Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Embase (Elsevier) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Hospital Premium Collection (ProQuest) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) ProQuest Central (ProQuest) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier)